Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Vaborbactam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
vaborbactam: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Relebactam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
relebactam: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lampalizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lampalizumab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Naratriptan Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
naratriptan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Samidorphan/olanzapine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
olanzapine samidorphan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Frovatriptan Succinate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
frovatriptan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Nelarabine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
nelarabine: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Brexanolone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
brexanolone: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eptinezumab-JJMR Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
eptinezumab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Brinzolamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
brinzolamide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lanthanum carbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lanthanum carbonate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Belatacept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
belatacept: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.